RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia
Released January 2019

Proceedings from Part 1 of a 2-part satellite symposia series during the 60th ASH Annual Meeting. Featuring perspectives from Drs Martin Dreyling, Jonathan W Friedberg, Brad S Kahl, Sonali M Smith and Michael E Williams. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

    OVERVIEW OF ACTIVITY
    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2018, and 58,100 individuals will die from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, including CLL, where the past several years have yielded a staggering number of important clinical and research advances.

    These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including CLL, with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering clinical presentation, biomarker profile and psychosocial status.
    • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
    • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, immune checkpoint inhibitors, chimeric antigen receptor-directed T-cell therapy) for the treatment of HL, non-Hodgkin lymphoma (NHL) and CLL to determine the current and/or potential utility of each in clinical practice.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of HL, NHL and CLL to support quality of life and continuation of treatment.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL and CLL, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHNHL2018/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Martin Dreyling, MD, PhD
    Professor of Medicine
    Department of Medicine III
    University Hospital – LMU Munich
    Munich, Germany

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Mundipharma International Limited, Roche Laboratories Inc, Sandoz Inc, a Novartis Division; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc; Other: Celgene Corporation, Janssen Biotech Inc, Roche Laboratories Inc.

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Data and Safety Monitoring Board: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, Gilead Sciences Inc, Kite Pharma Inc, Nordic Nanovector, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Seattle Genetics; Contracted Research: Celgene Corporation.

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite Pharma Inc, Sandoz Inc, a Novartis Division, Seattle Genetics, Takeda Oncology, TG Therapeutics Inc, Verastem Inc; Contracted Research with the University of Virginia: Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

    CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amy Bessnow, MD, MPH
    Seacoast Cancer Center
    Wentworth-Douglass Hospital
    Dover, New Hampshire

    No relevant conflicts of interest to disclose.

    Suzanne Cole, MD
    Medical Director
    University Hospital Simmons Cancer Clinic, Richardson-Plano
    Assistant Professor, Division of Hematology and Oncology
    UT Southwestern Medical Center
    Dallas, Texas

    No relevant conflicts of interest to disclose.

    Jewel Johl, MD
    Diablo Valley Oncology and Hematology Medical Group
    Pleasant Hill, California

    No relevant conflicts of interest to disclose.

    Kapisthalam S Kumar, MD
    Florida Cancer Specialists
    New Port Richey, Florida

    No relevant conflicts of interest to disclose.

    Erik Rupard, MD
    Chief, Hematology-Oncology
    McGlinn Cancer Institute
    The Reading Hospital
    West Reading, Pennsylvania

    No relevant conflicts of interest to disclose.

    Rajni Sinha, MD
    Piedmont Cancer Institute
    Atlanta, Georgia

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: January 2019
    Expiration date: January 2020

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Introduction

Chronic Lymphocytic Leukemia (CLL)

Hodgkin Lymphoma (HL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Diffuse Large B-Cell Lymphoma (DLBCL)

Select Publications